Abstract
Acalabrutinib is a selective Bruton tyrosine kinase inhibitor approved for patients with relapsed or refractory mantle cell lymphoma, an aggressive B-cell malignancy. Treatment-related adverse events (AEs) can have a negative effect on treatment adherence. This article aims to provide nurses with firsthand guidance so that they can better support patients with mantle cell lymphoma initiating acalabrutinib. Safety data from the acalabrutinib ACE-LY-004 phase 2 trial in 124 patients with relapsed or refractory mantle cell lymphoma were reviewed, and strategies implemented at the University of Texas MD Anderson Cancer Center to manage trial AEs are described. The most common AEs of any grade were headache and diarrhea, but no patients discontinued treatment because of them. When doses were missed or modified, patients were reeducated about the importance of adherence and how to manage AEs. Grade 1-2 AEs were managed with over-the-counter medication, if needed. These strategies allowed for the tracking of occurrences of nonadherence, providing the opportunity to advise and educate patients and to manage AEs more effectively.
References
May 2, 2002·Journal of the National Cancer Institute·Ann H PartridgeEric P Winer
Oct 27, 2007·Blood·Eva HosterUNKNOWN European Mantle Cell Lymphoma Network
Jul 11, 2008·Cancer·Yuhong ZhouMichael Wang
Jan 17, 2009·CA: a Cancer Journal for Clinicians·Kathryn RuddyAnn Partridge
Apr 8, 2009·Blood·Lucien NoensIvo Abraham
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David MarinJamshid S Khorashad
Feb 1, 2013·Acta Haematologica·Maria H de AlmeidaCarmino A de Souza
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Apr 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sabine Ponader, Jan A Burger
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Dec 4, 2014·Clinical Therapeutics·Henry J HenkJennifer Whiteley
Jan 13, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chan Yoon CheahMichael L Wang
Apr 5, 2017·Blood·Paul M BarrJohn C Byrd
Jul 13, 2017·American Journal of Hematology·Julie M Vose
Sep 9, 2017·The Journal of Pharmacology and Experimental Therapeutics·Tjeerd BarfAllard Kaptein
Dec 16, 2017·Lancet·Michael WangWojciech Jurczak
Feb 9, 2018·Haematologica·Anthony R MatoChaitra S Ujjani
Feb 14, 2018·Blood·Susan O'BrienJohn C Byrd
Sep 29, 2019·Leukemia·Michael WangMonika Długosz-Danecka